Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: a retrospective case series.
暂无分享，去创建一个
[1] G. Fabbrocini,et al. Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma , 2020, Dermatology and Therapy.
[2] A. Vidimos,et al. Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series. , 2020, Journal of the American Academy of Dermatology.
[3] A. Hauschild,et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] C. Costa,et al. Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single‐centre experience , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.